Scientists at the University of California at Chapel Hill School of Medicine, and Stanford University School of Medicine, have solved the high-resolution structure of psychedelix drugs such as LSD and psilocybin, when actively bound to the 5-HT2A serotonin receptor (HTR2A) on the surface of brain cells. The researchers say this first glimpse of how such drugs act at the molecular level will provide key insights into how they work, and could accelerate the discovery of fast-acting antidepressants and potentially drugs to treat additional neuropsychiatric conditions, such as severe anxiety and substance use disorder.
Metastasis in a mouse model of breast cancer inhibited by a peptide–drug conjugate that targets circulating cancer cells
Xencor licensed its XmAb® and Xtend™ technology platforms to Centocor Research & Development for the optimization of Centocor’s antibody drug candidates. Under the multiyear...
Researchers at the University of Washington School of Medicine Institute for Protein Design used computers to design small proteins that bind tightly to the SARS-CoV-2 Spike protein and prevent it from infecting human cells. The lead antiviral candidate, LCB1, appears to rival the most effective known SARS-CoV-2 neutralizing antibodies in protecting against the virus, and is currently undergoing evaluation in rodents.
X-Chem is entering a multi-target collaboration with Pfizer aimed at developing several programs for treating inflammatory and orphan diseases.
Primary endpoint was achieved, but secondary marker of OS is yet to be analyzed.
Part of the funding will be used to advance Jennerex' vaccines. The Ontario Institute for Cancer Research awarded a four-year, C$10 million ($8.9 million) grant...
Metastatic cancer could be warded off if drugs were to disrupt a form of cell-cell communication, the transfer of microRNAs from tumor cells to healthy cells via nanoscale conduits.
Roche’s GS FLX+ instrumentation was used, and some 131 billion base pairs of data were generated.
Researchers at the LIH Department of Infection and Immunity developed a novel molecule that binds to and blocks a previously unrecognized opioid receptor in the brain. The team’s studies showed that using the molecule to block this atypical opioid receptor, ACKR3, increases the availability of opioid peptides produced in the central nervous system (CNS) to bind to classical opioid receptors, effectively increasing their natural painkilling and antidepressant properties. They suggest their findings could point to the development of a novel class of drugs for treating pain, depression, and also brain cancer.